Published in J Clin Invest on May 01, 1992
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg (2008) 1.85
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet (2009) 1.57
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest (2016) 1.36
Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer (2004) 1.20
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta (2009) 1.18
Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol (2003) 1.11
Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol (1998) 1.05
Genetics and clinicopathological findings in thyroid carcinomas associated with familial adenomatous polyposis. Am J Pathol (1999) 1.01
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch (2004) 0.95
Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer (2000) 0.94
Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch (2007) 0.92
Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid (2008) 0.92
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br J Cancer (1993) 0.91
Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression. Endocr Pathol (2000) 0.91
Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol (2000) 0.90
Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch (2005) 0.90
Peroxisome proliferator-activated receptor-delta induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors. Cancer Res (2008) 0.87
Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation. Br J Cancer (1992) 0.86
Novel approaches in anaplastic thyroid cancer therapy. Oncologist (2014) 0.86
Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics (2011) 0.86
RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation. J Korean Med Sci (2005) 0.83
Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.83
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 0.82
Telomerase activity in benign and malignant human thyroid tissues. Br J Cancer (1998) 0.81
New treatment in advanced thyroid cancer. J Oncol (2012) 0.81
Rethinking the role of oncogenes in papillary thyroid cancer initiation. Front Endocrinol (Lausanne) (2012) 0.80
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol (2014) 0.80
Chromosomal rearrangements in post-Chernobyl papillary thyroid carcinomas: evaluation by spectral karyotyping and automated interphase FISH. J Biomed Biotechnol (2011) 0.79
Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res (2011) 0.78
Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma. Br J Cancer (1998) 0.78
Modeling anaplastic thyroid carcinoma in the mouse. Horm Cancer (2014) 0.77
Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes. Virchows Arch (2004) 0.77
Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark. World J Surg (2009) 0.77
Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor. J Inflamm (Lond) (2008) 0.76
The RET proto-oncogene: a challenge to our understanding of disease pathogenesis. Pediatr Surg Int (1997) 0.75
Previous external beam radiation treatment exposure does not confer worse outcome for patients with differentiated thyroid cancer. Thyroid (2016) 0.75
KAOS: a new automated computational method for the identification of overexpressed genes. BMC Bioinformatics (2016) 0.75
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
The molecular genetics of cancer. Science (1987) 7.64
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res (1988) 3.91
Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res (1989) 3.35
Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci U S A (1988) 2.99
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol (1987) 2.48
The approaching era of the tumor suppressor genes. Science (1987) 2.43
Developmentally regulated expression of a human "finger"-containing gene encoded by the 5' half of the ret transforming gene. Mol Cell Biol (1988) 2.21
Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene (1989) 2.17
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene (1989) 1.98
Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene (1988) 1.95
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene (1990) 1.52
Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol (1990) 1.50
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A (1992) 1.46
Activated ras oncogenes in human thyroid cancers. Cancer Res (1988) 1.45
Presence of mutations in all three ras genes in human thyroid tumors. Oncogene (1990) 1.42
gsp mutations in human thyroid tumours. Oncogene (1991) 1.37
Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene (1989) 1.28
cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun (1990) 1.27
High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res (1991) 1.14
Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. J Clin Invest (1991) 1.13
Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. Cancer (1990) 1.09
Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. Oncogene (1991) 1.07
Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene (1991) 1.06
H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab (1990) 0.96
Presence of aberrant transcripts of ret proto-oncogene in a human papillary thyroid carcinoma cell line. Jpn J Cancer Res (1989) 0.90
Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene (1991) 0.89
Thyroid cancer: pathologic and natural history. Recent Results Cancer Res (1980) 0.88
[ret gene from a human stomach cancer]. Hokkaido Igaku Zasshi (1988) 0.83
Host-Pathogen Interactions: IX. Quantitative Assays of Elicitor Activity and Characterization of the Elicitor Present in the Extracellular Medium of Cultures of Phytophthora megasperma var. sojae. Plant Physiol (1976) 6.80
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science (1984) 2.97
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (1995) 2.83
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery (2001) 2.50
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Thyroiditis: a clinical update. Mayo Clin Proc (1985) 2.31
Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab (1988) 2.20
AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract (2001) 2.15
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol Cell Biol (1993) 2.08
The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res (1998) 2.00
Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck (1994) 1.89
Central-nervous-system toxoplasmosis in homosexual men and parenteral drug abusers. Ann Intern Med (1984) 1.88
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene (1994) 1.87
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res (1996) 1.85
Thyroid carcinoma metastatic to the skin: a cutaneous manifestation of a widely disseminated malignancy. J Am Acad Dermatol (1997) 1.85
Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc (1986) 1.84
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am (1996) 1.75
Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo. Proc Natl Acad Sci U S A (2007) 1.73
Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab (1995) 1.71
bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood (1992) 1.69
One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol (1987) 1.66
Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery (2000) 1.63
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene (1992) 1.55
Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene (2006) 1.55
p53 activity and chemotherapy. Nat Med (1996) 1.53
The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene (1990) 1.52
Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51
Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res (1992) 1.50
Aberrant forms of bacteria and fungi found in blood or cerebrospinal fluid. Arch Intern Med (1969) 1.49
Structural features and selective expression of three Ly-5+ cell-surface molecules. Immunogenetics (1981) 1.47
The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A (1999) 1.47
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A (1992) 1.46
CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood (1993) 1.44
Arabidopsis glucosidase I mutants reveal a critical role of N-glycan trimming in seed development. EMBO J (2001) 1.43
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery (1994) 1.41
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39
The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol (1995) 1.38
Letter: Thyrotoxic periodic paralysis in Britain. Br Med J (1975) 1.38
Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery (1991) 1.38
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res (1995) 1.33
Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet (1995) 1.33
A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene (2000) 1.33
Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.33
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Follicular thyroid cancer. Endocrinol Metab Clin North Am (1995) 1.31
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest (2000) 1.30
Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res (1998) 1.29
Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg (1990) 1.29
Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene (2007) 1.28
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Thyroglossal duct carcinoma: report of 12 cases. Mayo Clin Proc (1997) 1.27
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26
Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer (2001) 1.26
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res (1994) 1.22
Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery (1988) 1.20
Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol (1994) 1.20
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online. Hum Mutat (1998) 1.19
A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nat Genet (1993) 1.18
The human eps15 gene, encoding a tyrosine kinase substrate, is conserved in evolution and maps to 1p31-p32. Oncogene (1994) 1.18
Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res (1997) 1.18
Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol (1997) 1.18